At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Corifollitropin Alfa +3 moredrug
Likely dose
Corifollitropin Alfa 150 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Continuous Ovarian Stimulation in DUOSTIM Cycles.
In Brief
A Phase 4 clinical trial evaluating Corifollitropin Alfa, Follitropin Alfa, and 2 other interventions for Fertility Issues. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFertility Issues
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedApr 2023
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedApr 18, 2023
Enrollment StartNov 17, 2022
Primary CompletionApr 30, 2023
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.2 years ago
Interventions
Corifollitropin Alfadrug
150 micrograms per dose
Follitropin Alfadrug
Variable dose.
Follitropin Alfa Biosimilardrug
Variable dose.
Urinary Human follicle stimulating hormonedrug
Variable dose.